Malignant Glioma Therapeutics Market By Therapeutic Type (Chemotherapy, Immunotherapy, Targeted Therapy); By Drug Class (Chemotherapeutic Agents, Monoclonal Antibodies, Immunomodulatory Agents); By End User (Hospitals, Specialized Oncology Centers, Research Institutions); By Region (North America, Europe, Asia-Pacific, LAMEA); Segment Revenue Estimation, Forecast, 2026–2032

Malignant Glioma Therapeutics Market: Biomarker Selection, Repeat Treatment and Access Gaps Shape Neuro-Oncology Demand

The Global Malignant Glioma Therapeutics Market is estimated to reach USD 1.63 billion in 2025 and is projected to grow to USD 2.88 billion by 2032, expanding at a CAGR of 8.5% during the forecast period, according to Strategic Market Research.

 

The malignant glioma therapeutics market spans neurosurgery, radiotherapy, drug treatment, molecular diagnostics and device-based care. Surgery or biopsy typically begins the treatment pathway by confirming diagnosis and reducing tumor burden. Demand then moves toward focal radiotherapy, temozolomide, therapies for recurrent disease, biomarker-selected treatments and, where available, tumor-treating fields.

 

Molecular testing increasingly guides treatment selection and prognosis. MGMT promoter methylation is associated with greater sensitivity to temozolomide, while IDH1 and IDH2 mutations identify gliomas with distinct biology and generally better outcomes. The 1p/19q codeletion confirms oligodendroglioma and predicts greater responsiveness to chemotherapy and radiotherapy. EGFR amplification may support targeted-treatment or clinical-trial selection, while TERT promoter mutations help identify more aggressive molecular profiles.

 

Glioblastoma represents the largest commercial segment, alongside grade 3 and grade 4 astrocytomas, recurrent high-grade gliomas and rare molecular subtypes, including H3 K27M-mutant diffuse midline glioma. These patient groups vary by age, tumor location, molecular profile, treatment eligibility and reimbursement. 

 

Global Brain-Cancer Burden Provides Context, but Glioblastoma Must Be Reported Separately

GLOBOCAN 2024 estimates 324,095 new brain and central nervous system cancer cases and 248,964 related deaths worldwide. Asia represented 182,499 cases, or 56.3% of global incidence, followed by Europe with 63,079 cases, Northern America with 27,823, Latin America and the Caribbean with 27,774, Africa with 20,191 and Oceania with 2,729. These totals include all malignant brain and CNS cancers and should not be reported as glioblastoma-specific figures.

This broader disease burden is commercially relevant because it supports demand for neurosurgery, MRI, neuropathology, molecular testing, radiotherapy and oncology services. However, it does not directly measure treatment use or regional market revenue. Asia records the highest case volume, while the United States and several European markets have stronger reimbursement systems and greater adoption of premium therapies.

The widely cited estimate of about 250,000 new glioblastoma cases annually is not supported by current population registries and may reflect confusion with the broader brain and CNS cancer category. Estimates approaching 200,000 annual glioblastoma deaths should also be treated cautiously. Most international datasets report mortality under combined brain and CNS cancer classifications rather than by specific tumour subtype.

 

Glioblastoma Accounts for More Than Half of U.S. Malignant Brain Tumors

The latest Central Brain Tumor Registry of the United States report projects 26,480 new malignant brain and CNS tumors in 2025, including 13,930 glioblastomas. Glioblastoma represented 52.2% of malignant primary brain and CNS tumors diagnosed during 2018–2022, making it the largest individual malignant histology and the principal patient pool for surgery, chemoradiation, maintenance temozolomide and TTFields.

This evidence supports an annual U.S. glioblastoma population of approximately 14,000 patients, rather than the broader estimates of 17,000–22,000 sometimes attributed to all malignant gliomas. The wider malignant-glioma population includes IDH-mutant grade 3 and grade 4 astrocytomas, molecularly defined high-grade tumors and malignant gliomas that are not otherwise specified.

CBTRUS recorded an average of 17,637 annual U.S. deaths from all malignant primary brain and CNS tumors during 2018–2022. This cannot be treated as a glioma-only death count because the category also includes CNS lymphomas and other malignant histologies. The figures nevertheless demonstrate the high mortality burden and the continuing need for treatments that produce durable control after initial surgery.

 

Maximal Safe Resection Remains the Gateway to Recurring Treatment

For operable tumors, maximal safe resection remains the principal entry point. The objective is not simply procedure volume; the extent of resection can affect postoperative fitness, residual disease and eligibility for additional therapies. Biopsy remains necessary when extensive removal would create unacceptable neurological risk.

The current pathway uses focal radiotherapy rather than routine whole-brain radiotherapy. Eligible newly diagnosed glioblastoma patients generally receive radiotherapy with concurrent oral temozolomide, followed by maintenance temozolomide. The FDA updated the temozolomide label in 2023 to reflect its use with radiotherapy and then as maintenance treatment in newly diagnosed glioblastoma.

NICE recommends 60 Gy in 30 fractions with concomitant temozolomide followed by up to six adjuvant cycles for many fit patients aged around 70 or younger. Shorter radiotherapy schedules and molecularly guided temozolomide use are considered for older patients. These criteria show why age, functional status and MGMT promoter methylation influence the addressable drug-treated population.

Surgery-linked carmustine implants occupy a narrower segment. NICE limits their use to selected newly diagnosed high-grade glioma patients when at least 90% of the tumor has been resected. Demand is therefore concentrated in advanced neurosurgical centers and depends directly on operative outcome, rather than on total glioma incidence.

 

Temozolomide Provides Volume, but Generic Competition Restricts Value Growth

Temozolomide remains the pharmaceutical backbone of newly diagnosed glioblastoma treatment. Its oral administration creates demand through concurrent radiotherapy and subsequent maintenance cycles, including outpatient and specialty-pharmacy channels. It is also used in selected anaplastic astrocytoma and recurrent glioma pathways.

The segment is commercially mature. Multiple generic products have reduced the pricing power of the reference brand, shifting competition toward formulary placement, supply reliability, procurement contracts and geographic availability. Growth in temozolomide revenue is consequently more dependent on treated-patient conversion and access in emerging healthcare systems than on product differentiation.

MGMT methylation testing has become commercially important because it helps clinicians assess likely benefit from temozolomide, particularly in older patients for whom treatment intensity must be balanced against toxicity and functional status. Molecular testing therefore influences both drug selection and the number of patients who progress into maintenance treatment.

 

Recurrent Disease Creates Repeated Treatment Decisions but No Uniform Standard

Recurrence generates demand for repeat surgery, reirradiation, lomustine, temozolomide rechallenge, bevacizumab, clinical-trial therapies and supportive care. Treatment selection depends on performance status, tumor location, molecular characteristics, previous therapy and time since the last treatment.

Lomustine remains an established recurrent high-grade glioma option and frequently acts as a comparator in clinical trials. Bevacizumab has an FDA indication for recurrent glioblastoma in adults and generates hospital or infusion-center demand, but biosimilar competition limits originator pricing power. Its commercial position also varies geographically: NICE does not recommend bevacizumab for recurrent high-grade glioma within the NHS pathway.

This fragmentation limits the ability of any single recurrent therapy to capture the entire population. The segment provides repeated treatment opportunities, but individual regimens compete with clinical trials, best supportive care and further local intervention.

 

TTFields Creates a Premium Patient-Month Revenue Model

Optune Gio delivers tumor-treating fields through a portable wearable system. In the United States, it is used with maintenance temozolomide for eligible adults with newly diagnosed glioblastoma after surgery and chemoradiation. The commercial model differs from conventional equipment sales because treatment generates recurring demand for the device platform, disposable arrays, patient support and monthly payer billing.

CMS covers TTFields for qualifying Medicare beneficiaries with newly diagnosed glioblastoma when specified clinical and treatment-sequence requirements are met. This makes documentation of surgery, chemoradiation, performance status and treatment timing part of the commercial conversion process.

Novocure reported 4,543 active Optune Gio patients worldwide as of March 31, 2026, up 9% year over year. This included 2,250 patients in the United States, 641 in Germany, 503 in France and 535 in Japan, with another 614 across other active markets. These are direct measures of recurring product adoption rather than estimates based on disease incidence.

Access remains payer-dependent. NICE does not recommend TTFields for newly diagnosed or recurrent high-grade glioma, producing a clear difference between U.S. Medicare-supported adoption and NHS practice. Premium neuro-oncology technologies therefore require country-specific health-economic evidence rather than regulatory approval alone.

The Phase 3 TRIDENT trial tested whether starting TTFields during chemoradiation was superior to beginning it during maintenance. The 981-patient study did not meet its primary overall-survival endpoint. Median overall survival was 17.7 months in the early-start arm and 17.5 months in the maintenance-start arm. The result limits the immediate commercial case for expanding TTFields into the earlier chemoradiation period while leaving the existing maintenance-stage position separately intact.

 

Modeyso Establishes a New Molecularly Defined Commercial Segment

The most important recent pharmaceutical development is the August 2025 FDA accelerated approval of Modeyso, or dordaviprone, for adults and children aged one year and older with progressive H3 K27M-mutant diffuse midline glioma following previous therapy. It became the first FDA-approved systemic treatment for this molecular subtype.

The epidemiological population is small. CBTRUS recorded 1,160 H3 K27M-mutant diffuse midline glioma cases during 2018–2022, with an incidence rate of 0.08 per 100,000 and a median diagnosis age of 16 years. Not all of these patients would meet the progressive-disease and prior-treatment requirements in the approved label.

Despite the narrow patient base, Jazz Pharmaceuticals reported USD 41.4 million in Modeyso net sales during the first quarter of 2026 and approximately 500 patients treated between its August 2025 launch and the end of March 2026. The launch demonstrates how biomarker selection, limited alternatives and high unmet need can create material revenue from a rare population.

The ongoing Phase 3 ACTION trial is evaluating dordaviprone after radiotherapy in newly diagnosed, non-recurrent H3 K27M-mutant diffuse glioma. Jazz expects topline results in late 2026 or early 2027. Positive confirmatory evidence could strengthen the accelerated approval and extend treatment into an earlier, potentially larger patient setting.

 

Pipeline Investment Is Moving Toward Biomarker-Directed and Locally Delivered Therapies

Checkpoint inhibitors, personalized vaccines, oncolytic viruses and CAR T-cell therapies remain under investigation, but none has replaced temozolomide-based chemoradiation as the broad newly diagnosed glioblastoma standard. The immunosuppressive tumor environment, limited immune-cell penetration, antigen heterogeneity and blood-brain barrier remain substantial development risks.

Current cellular-therapy programs increasingly use multiple targets or local intracranial administration to reduce antigen escape. Active studies include approaches directed at EGFR, IL13Rα2, CD70, GPC3 and other glioma-associated antigens. These programs remain early stage and should be treated as pipeline optionality rather than near-term commercial volume.

Early results in H3 K27M-mutant diffuse midline glioma have provided a development signal. An NCI-reviewed study of GD2-directed CAR T cells reported neurological improvement in nine of 11 treated patients and tumor shrinkage in seven. The patient count is too small to establish a standard of care, but the results support continued investment in biomarker-defined cellular therapy for tumors with few treatment options.

 

Regional Demand Reflects a Mismatch Between Case Burden and Revenue Access

Asia represents more than half of worldwide brain and CNS cancer incidence, but treatment access varies substantially across the region. Demand for affordable temozolomide, neurosurgery and radiotherapy is larger than current adoption of premium therapies. Japan provides an exception, with 535 active Optune Gio patients reported in March 2026.

North America has a smaller share of global case volume than Asia but offers stronger commercial conditions for branded and device-based treatments through specialist centers, molecular testing, Medicare coverage and clinical-trial infrastructure. The United States accounted for almost half of Novocure’s reported active Optune Gio population and was the initial launch market for Modeyso.

Europe combines advanced neuro-oncology capacity with strict health-technology assessment. Germany and France have established Optune adoption, while NICE’s negative recommendation restricts routine NHS use in England. Regional revenue therefore cannot be inferred from patient numbers alone.

Lower-resource markets face delayed diagnosis, limited neurosurgical and radiotherapy capacity and lower access to molecular testing. Generic chemotherapy can expand earlier than premium biomarker-directed or device-based treatments because it requires less complex reimbursement and patient-support infrastructure.

 

Competitive Value Is Dividing Between Commoditized Volume and High-Value Niches

The competitive landscape is divided into three commercial models:

• Volume-based generic treatment: Temozolomide and lomustine depend on treatment rates, procurement and reliable supply, with limited molecule-level pricing power.

• Hospital-infused recurrent treatment: Bevacizumab and its biosimilars generate recurring administration demand but face payer-led substitution and hospital contracting pressure.

• Premium differentiated platforms: Modeyso and Optune Gio derive value from molecular selection, limited alternatives, proprietary technology, patient support and treatment duration.

Merck & Co. remains associated with the reference temozolomide product, Roche and Genentech with bevacizumab, Novocure with TTFields and Jazz Pharmaceuticals with dordaviprone. Competitive advantage increasingly depends on control of the complete treatment pathway, including testing, specialist referral, payer authorization, patient onboarding and persistence.

 

Market Outlook

Near-term malignant glioma therapeutics revenue will continue to rely on temozolomide-based multimodality care and recurrent-treatment decisions. However, the strongest value creation is moving toward molecularly selected rare-glioma treatments and recurring device-supported therapy.

Modeyso provides direct evidence that a small mutation-defined population can support meaningful commercial sales when there is no established systemic alternative. Optune Gio shows that a recurring patient-month model can build an international treated base, although the TRIDENT result limits assumptions about expansion into earlier treatment.

 

Malignant Glioma Therapeutics Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.63 Billion
Revenue Forecast in 2032	USD 2.88 Billion
Overall Growth Rate	CAGR of 8.5% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
By Therapeutic Type	Chemotherapy; Immunotherapy; Targeted Therapy
By Drug Class	Chemotherapeutic Agents; Monoclonal Antibodies; Immunomodulatory Agents
By End User	Hospitals; Specialized Oncology Centers; Research Institutions
By Region	North America; Europe; Asia-Pacific; LAMEA
Market Drivers – Increasing Need for High-Grade Glioma Treatment	Rising malignant glioma burden, limited survival outcomes, and continued demand for improved treatment options are supporting investment in chemotherapy, targeted therapies, and advanced neuro-oncology solutions.
Market Drivers – Growth of Biomarker-Guided Therapies	Increasing adoption of molecular testing, including MGMT, IDH mutations, 1p/19q codeletion, and H3 K27M classification, is enabling more personalized treatment approaches.
Market Drivers – Expansion of Premium Neuro-Oncology Platforms	Growth in tumor-treating fields, molecularly targeted therapies, and specialty oncology treatments is creating higher-value opportunities beyond conventional chemotherapy.
Customization Option	Available upon request